RISK FACTORS FOR CANCER IN RENAL TRANSPLANT RECIPIENTS1
- 1 December 1999
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 68 (12) , 1859-1864
- https://doi.org/10.1097/00007890-199912270-00008
Abstract
Cancer continues to be an important cause of morbidity and mortality after renal transplantation. Unfortunately, risk factors for cancer have not been well defined. We examined risk factors for invasive, life-threatening malignancies among 1500 renal transplant recipients. Both univariate and multivariate Cox proportional hazards analyses were used. There were 87 tumors in 88 patients. Actuarial survival free of cancer was 95.9% at 5 years, 92.3% at 10 years, 86.6% at 15 years, and 82.6% at 20 years. Among multiple possible risk factors, the adjusted, relative risk attributable to age at transplantation (compared to age <45 years) was 2.00 (95% confidence interval: 1.21-3.30, P=0.007) for age ≥45 and <60 years (29.1% of total were in this age range), and 3.81 (95% confidence interval: 2.05-7.06, P<0.001) for age ≥60 years (11.6%). The relative risk attributable to pretransplant splenectomy (47.8%, now large abandoned) was 1.87 (95% confidence interval: 1.12-3.12, P=0.016). Patients with renal disease from type 1 diabetes had a lower risk of cancer, 0.19 (95% confidence interval: 0.05-0.08, P=0.015). A history of invasive cancer pretransplant (2.5%) increased the risk of posttransplant cancer to 2.38 (95% confidence interval: 1.18-4.83, P=0.015). Cigarette smoking was also associated with an increased risk, with each 10 pack-years smoked at transplant increasing the risk of cancer by 1.12 (1.02-1.21, P=0.016). The era when transplantation occurred, the type of prophylactic immunosuppression used, the occurrence of acute rejection, or its treatment did not alter the risk of cancer. The risk of cancer continues to increase 15-20 years after transplantation. The identification of splenectomy as a new risk factor, even several years after this immunosuppression strategy has been abandoned, demonstrates that the risk of immunosuppression may take years to become manifest. Efforts to reduce immunosuppression, particularly for patients ≥45 years of age at transplant, along with a greater effort to discourage cigarette smoking, may help reduce the risk of cancer after renal transplantation.Keywords
This publication has 20 references indexed in Scilit:
- Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimensThe Lancet, 1998
- Smoking after heart transplantation: An underestimated hazard?European Journal of Cardio-Thoracic Surgery, 1997
- Lymphoma incidence, cyclosporine, and the evolution and major impact of malignancy following organ transplantationTransplantation Proceedings, 1997
- Malignancies in patients under long-term immunosuppression after kidney transplantationTransplantation Proceedings, 1997
- Malignancy after renal transplantation: Analysis of incidence and risk factors in 1700 patients followed during a 25-Year periodTransplantation Proceedings, 1997
- The Agency for Health Care Policy and Research Smoking Cessation Clinical Practice GuidelineJAMA, 1996
- Malignancies after renal transplantation: the EDTA-ERA registry experienceNephrology Dialysis Transplantation, 1995
- Incidence of non-hodgkin lymphoma in kidney and heart transplant recipientsThe Lancet, 1993
- Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease.Journal of Clinical Oncology, 1993
- Malignant Tumours in Renal Transplant Recipients Receiving Cyclosporin: Survey of 598 First-Kidney TransplantationsNephrology Dialysis Transplantation, 1990